Septerna, Inc. $SEPN Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) by 15.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,451 shares of the company's stock after selling 21,165 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.27% of Septerna worth $686,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in SEPN. Tower Research Capital LLC TRC purchased a new position in Septerna in the fourth quarter valued at about $25,000. KLP Kapitalforvaltning AS purchased a new position in Septerna in the first quarter valued at about $49,000. BNP Paribas Financial Markets purchased a new position in Septerna in the fourth quarter valued at about $52,000. Rhumbline Advisers increased its holdings in Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock valued at $135,000 after buying an additional 3,323 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Septerna in the first quarter valued at about $216,000.

Septerna Stock Up 2.2%

Shares of SEPN traded up $0.31 during mid-day trading on Friday, reaching $14.43. 202,291 shares of the company's stock were exchanged, compared to its average volume of 262,803. The company has a 50-day simple moving average of $12.11 and a two-hundred day simple moving average of $9.14. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99. The company has a market cap of $643.29 million and a price-to-earnings ratio of -1.43.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million for the quarter, compared to analysts' expectations of $22.50 million. As a group, equities research analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SEPN shares. HC Wainwright reaffirmed a "buy" rating and issued a $26.00 target price on shares of Septerna in a report on Thursday, August 21st. Wall Street Zen raised shares of Septerna from a "sell" rating to a "hold" rating in a report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Septerna in a report on Friday. Finally, Wells Fargo & Company increased their target price on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Septerna currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.